Johnson & Johnson Family of Companies
NEWS
Under an agreement with Johnson & Johnson’s Actelion Pharmaceuticals, the rights to the multiple sclerosis drug Ponvory in the U.S. and Canada will be transferred to Vanda Pharmaceuticals.
Ten of the anticipated assets have the potential to deliver $5 billion or more in peak year sales, while another 15 of the candidates have a $1 billion to $5 billion PYS potential, according to Johnson & Johnson.
Johnson & Johnson’s AI investments include a research facility in San Francisco and a data science workforce of approximately 6,000 employees.
The two companies have settled all pending U.S. patent litigation, clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed biosimilar of Stelara.
The agency on Tuesday said it is investigating the “serious risk” of T cell malignancy outcomes, including hospitalization and death, and evaluating the need for potential regulatory action.
J&J, AbbVie, Genmab and Genentech are presenting new data at next month’s American Society of Hematology meeting on the therapeutic potential of their therapies in multiple myeloma and mantle cell lymphoma.
Social media campaigns may have been one factor that prompted Johnson & Johnson and Danaher to make a TB treatment and a test more accessible in low- and middle-income countries.
The Department of Health and Human Services in a court filing last week said that the blockbuster treatment could be “deselected” from the drug price negotiation list, given the recent approval of Amgen’s Stelara biosimilar.
Fresh off of his Sanofi exit, John Reed is joining Johnson & Johnson, where he will serve as executive vice president, pharmaceuticals, R&D.
JOBS
IN THE PRESS